BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
BRUNO DOMON	Director Luxembourg Clinical Proteomics Center Professor University of Luxembourg
CURRENT AFFILIATION Luxembourg Clinical Proteomics Center, CRP-Sante,	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
National Department of Education, France	*Habilitation as Professor of University*	*1994*	*Biochemistry Section*
MIT, Cambridge, USA	*Post-doctoral fellow*	*1986-87*	*Mass spectrometry*
Ciba-Geigy, Basel, Switzerland	*Post-doctoral fellow*	*1985*	*Mass spectrometry*
University of Lausanne, Switzerland	*Ph.D. (Doctorate es Sciences)*	*1981-84*	*Analytical Chemistry*
University of Neuchatel, Switzerland	*Chemical Engineer Degree,*	*1975-80*	
Gymnase français de Bienne, Switzerland	*'Certificat de Maturité', type C*	*1972-75*	

List of five recent publications by the candidate:

- B. Domon, R. Aebersold; *Mass Spectrometry and Protein Analysis*; Science, 312: 212-217 (2006)
- P. Picotti, B. Bodenmiller, L.N. Mueller, B. Domon, R. Aebersold; *Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics*. Cell,;138: 795-806.(2009).
- B. Domon, R. Aebersold; *Options and considerations when selecting a quantitative proteomics strategy*. Nat. Biotechnol. 28: 710-721 (2010).
- R. Kiyonami, A. Schoen, A. Prakash, S.Peterman,V. Zabrouskov, P.Picotti, R. Aebersold, A. Huhmer, B. Domon; *Increased selectivity, analytical precision, and throughput in targeted proteomics*. Mol. Cell. Proteomics.10:2 (2011); DOI 10.1074/mcp.M110.002931
- N. Selevsek, M. Matondo, M. Sanchez Carbayo, R. Aebersold, B. Domon; *Systematic Quantification of Peptides / Proteins in Urine Using Selected. Reaction Monitoring*, Proteomics, 11: 1135-1147 (2011).

Please indicate in 200 words or less the reason(s) why you would be a suitable candidate for the HUPO Council elections.

Since the 1980s Bruno Domon has applied novel techniques to characterize proteins and glycoproteins in academia and in the pharmaceutical/biotech industry. At MIT he pioneered, with Catherine E. Costello, the MS/MS fragmentation of glycoconjugates, and developed a systematic nomenclature. He worked in the industry (1988 – 2000), heading the mass spectrometry facility at Ciba in Basel and then at Biogen in Cambridge, USA. He went on to head the large-scale proteomics facility at Celera Genomics in Rockville, MD (2001-2004), then joined the group of Ruedi Aebersold at ETH Zurich (2004-2009), where he worked, as group leader, to develop alternate proteomics workflows and targeted approaches based on selected reaction monitoring, expanding this technology to encompass large-scale screening.

In 2010 Domon assumed leadership of the new Luxembourg Clinical Proteomics Center (LCP), and now heads the effort to develop high-throughput quantitative mass spectrometry methods to qualify and biomarkers in bodily fluids, with the goal of translating them into routine clinical assays. LCP is part of a wider effort in Luxembourg to push the envelope of translational biomedical research.

A member of HUPO's Membership Committee since 2007, Bruno Domon has served as its chair since 2010. He joined HUPO's Financial Committee in 2011.